Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Elitek
Rasburicase is a recombinant urate oxidase enzyme used to manage and prevent hyperuricemia, a condition characterized by elevated uric acid levels in the blood. This condition is often a complication of chemotherapy for hematologic malignancies, particularly in patients with high tumor burden. Rasburicase catalyzes the oxidation of uric acid into allantoin, a more soluble compound that is readily excreted by the kidneys. It is a biologic drug administered intravenously.
For the initial management and prevention of hyperuricemia in patients with certain cancers undergoing chemotherapy.
Severe allergic reactions including anaphylaxis and methemoglobinemia have been reported. Hemolysis may also occur in patients with G6PD deficiency.
Outcome:
Decreased effectiveness of rasburicase
Mechanism:
Allopurinol inhibits xanthine oxidase, an enzyme involved in uric acid production. This can reduce the substrate available for rasburicase.
Outcome:
Potential alteration in INR levels
Mechanism:
Uric acid can displace warfarin from protein binding sites, potentially affecting INR levels.
Outcome:
No clinically significant interaction expected
Mechanism:
No known significant interaction mechanism.
Most likely new formulation: subcutaneous injection (Year 2026, 60% confidence)
Based on current usage trends and ongoing clinical trials, there is a 70% likelihood of expanded indications for rasburicase in the next 5 years.
Urate Oxidase Enzyme, Antineoplastic Adjunct
Recombinant protein